Front. Endocrinol. Frontiers in Endocrinology Front. Endocrinol. 1664-2392 Frontiers Media S.A. 10.3389/fendo.2025.1736207 Correction Correction: Case series: ATRX variants in four patients with metastatic pheochromocytoma CortezBriana N. 1 Formal analysis Writing – original draft Methodology Conceptualization Investigation Data curation Writing – review & editing KuoMickey J. M. 1 2 Data curation Formal analysis Methodology Investigation Writing – review & editing Conceptualization Writing – original draft JhaAbhishek 1 Writing – review & editing Formal analysis Investigation Software Data curation Methodology Writing – original draft Conceptualization PatelMayank 1 3 Data curation Formal analysis Methodology Investigation Software Conceptualization Writing – review & editing Writing – original draft CarrasquilloJorge A. 4 Methodology Formal analysis Investigation Writing – review & editing ProdanovTamara 1 Data curation Writing – review & editing CharlesKailah M. 1 Writing – review & editing Data curation TalvacchioSara 1 Data curation Writing – review & editing DerkyiAlberta 1 Writing – review & editing Data curation LinFrank I. 4 Writing – review & editing TaïebDavid 5 Validation Writing – review & editing Del RiveroJaydira 6 Validation Writing – review & editing PacakKarel 1 * Project administration Writing – review & editing Supervision Methodology Writing – original draft Validation Visualization Investigation Data curation Resources Conceptualization Formal analysis Funding acquisition Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, United States Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States Department of Nuclear Medicine, La Timone University Hospital & Centre de Recherches en Cancérologie de Marseille (CERIMED) & French Institute of Health and Medical Research (Inserm) UMR1068 Marseille Cancerology Research Center, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France Developemental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States Correspondence: Karel Pacak, karel@mail.nih.gov 14 11 2025 2025 16 1736207 30 10 2025 31 10 2025 Copyright © 2025 Cortez, Kuo, Jha, Patel, Carrasquillo, Prodanov, Charles, Talvacchio, Derkyi, Lin, Taïeb, Del Rivero and Pacak. 2025 Cortez, Kuo, Jha, Patel, Carrasquillo, Prodanov, Charles, Talvacchio, Derkyi, Lin, Taïeb, Del Rivero and Pacak https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Case series: ATRX variants in four patients with metastatic pheochromocytoma By Cortez BN, Kuo MJM, Jha A, Patel M, Carrasquillo JA, Prodanov T, Charles KM, Talvacchio S, Derkyi A, Lin FI, Taïeb D, Del Rivero J and Pacak K (2024) Front. Endocrinol. 15:1399847. doi: 10.3389/fendo.2024.1399847 case report pheochromocytoma ATRX prognosis imaging section-at-acceptance Adrenal Endocrinology

The Conflict of interest statement was erroneously given as “The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest”. The correct Conflict of interest statement is “DT is a founder, stakeholder, and the Chief Medical Officer of SilonTx, a company with interest in molecular medicine and nuclear medicine for cancer and rare diseases. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland